Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Gynecologic Oncology
SGO 2025
Questions discussed in this category
What are your top takeaways from SGO 2025?
3 Answers available
23450
Papers discussed in this category
Lancet (London, England), 2024 Mar 20
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lancet (London, England), 2024 Oct 11
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.
Related Topics in Gynecologic Oncology
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Genitourinary Cancers
Melanoma/Skin Cancer
